Why Asimov is interesting

Programming living cells for biologics, cell/gene therapy, RNA — MIT/BU founders with $200M+ raised.

Key facts

• Seed (2017): led by a16z (TechCrunch)
• Series B (2023): $175M led by CPP Investments with a16z participation (company press)
• Co-investors: no additional institutional investors in VCT directory disclosed in public sources reviewed 2026-07-24

Investors in our directory

Funds linked from Asimov's profile — open a fund page for stage focus and related deal articles.

Industries

Industry hub pages are rolling out from our fund-derived baseline taxonomy.

Related funding articles

Venture Capital Tracker pieces that cover Asimov's financing or category context.

• a16z Portfolio Companies on Fire in 2026: AI, American Dynamism & More